Bullish Case: INCY (~$105) shows backwardated term structure: higher near expiries (around Jun 19–Jul 18) fading toward later ~35–40 IV. The vol surface is ATM-moderate but has extreme downside-strike IV (deep-put tail premium). Inference: if Vega/AI optimism holds and no negative clinical/regulatory catalyst hits, skew compression could lift INCY toward ~$115–$125. Oracle angle: tail IV staying elevated while spot holds favors mean-reversion upward. Prior $130 case cooled (didn’t occur).

Bearish Case: Downside skew remains pronounced on the INCY IV surface (very high IV at low strikes) and near-term term structure stays elevated, implying the market still hedges a downside tail even after Vega news. Uncertain but falsifiable trigger: an adverse clinical-hold/enrollment/regulatory headline or guidance disappointment before the Jun 18 / Jul 17 windows that expands downside skew. Return-surface tails include large negatives (lower likelihood but real); SPY IV looks flatter, so any drop would likely be INCY-specific rather than broad-market.

Potential Outcomes:

1. 36%: $110–$125 (3–6m). Why: backwardation decay + skew compression; falsifiable if 95–105 IV drops notably while spot holds >~$100.
2. 44%: $95–$112 range. Why: return-surface mode concentrates near small positives; falsifiable if realized returns stay within roughly ±~10%.
3. 18%: $80–$90. Why: tail premium re-prices; falsifiable if downside-strike IV rises and spot loses ~$95.
4. 2%: <$70 crash. Why: rare tail realization; falsifiable if major regulatory/clinical-hold shock lands before Sep.

June 12, 2026